Neurogen Biomarking, a digital health platform for memory and thinking concerns, has announced an agreement with Quanterix to support the early detection of dementia and mild cognitive impairment (MCI) associated with Alzheimer’s disease (AD).
This partnership will leverage Quanterix’s antibody technology to detect a blood biomarker, which serves as an early indicator of dementia and MCI.
Quanterix specialises in ultrasensitive biomarker detection technology. In February 2024, the company announced a collaboration with five health networks to aid the diagnosis and clinical management of individuals with AD.
Under this agreement, Neurogen Biomarking will have exclusive rights to market Quanterix’s ultrasensitive technology for direct-to-consumer use in the US, Europe, and pan-Asia.
Neurogen Biomarking CEO and founder Rany Aburashed said: “Neurogen Biomarking’s agreement with Quanterix brings us one step closer to shifting the current standard of care paradigm for detection of Mild Cognitive Impairment and dementia due to Alzheimer’s by giving people easier access to clinically validated blood biomarker technology.
“Our driving force is to solve the issue of delayed detection and ultimately diagnosis by empowering patients in a responsible, scientifically and clinically controlled scalable ecosystem while also guiding them every step of the way in their brain health journey.”
Neurogen Biomarking’s care ecosystem offers an at-home blood biomarker collection test to measure phosphorylated tau 217 (P-tau217), a specific marker for AD pathology and MCI, using Quanterix’s ultrasensitive technology.
The platform allows patients to initiate the process and access telehealth consultations with board-certified neurologists. It provides personalised health education and a tailored Brain Health Plan with actionable next steps for individualised care.
Neurogen Biomarking’s platform will be available in early Q2 of 2025 for individuals with memory and thinking challenges, as well as those concerned about early AD symptoms.
Last month, the digital health platform partnered with Linus Health to integrate its digital cognitive assessments into the Neurogen Biomarking ecosystem.
In January, Quanterix also signed an all-stock deal to acquire Akoya Biosciences to create an integrated solution for the detection of blood- and tissue-based protein biomarkers.
